Subcutaneous Dosing Schedule and Chair-Time Advantage

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, walks through the dosing schedule and administration of subcutaneous amivantamab in cohort 1 of the OrigAMI-4 study. He explains that patients received a weekly loading dose for the first 3 weeks, followed by administration once every 3 weeks, and notes that future studies are evaluating a once-every-4-week schedule that could offer additional dosing flexibility. Unlike intravenous amivantamab, Dr Swiecicki reports that the subcutaneous formulation produced no infusion-related reactions in this study; instead, administration-related reactions occurred, all grade 2 or lower, seen in 6% of patients at grade 2 and 9% at grade 1. He contrasts this favorably with the longer infusion-chair time required for intravenous administration, positioning subcutaneous dosing as a more convenient option for patients and infusion centers.